Pune, India, Aug. 03, 2021 (GLOBE NEWSWIRE) -- The Global Meibomian Gland Dysfunction Treatment Market has been estimated to reach a value of USD 158.6 billion in 2021 and is...
(Reuters) - Takeda Pharmaceutical Co said on Monday it will record a provision of about 63 billion yen ($574.56 million) in its financial statements for the first quarter to...
The FTC has decided to drop an antitrust complaint against AbbVie alleging the drugmaker lodged "sham" patent complaints to delay competition of AndroGel.
AbbVie (ABBV), a leader in key therapeutic sectors, including immunology, hematologic oncology, neuroscience, aesthetics, ophthalmology and women's health, shot to the top of the...
Stocks slipped from their records through mid-afternoon trading on Tuesday. The Nasdaq was down 2%, while the S&P 500 had slipped 1%, and the Dow dipped 0.70%. The downturn...
Last weeks’ turbulent market is about to head into another. The intensity of the upcoming turbulence will depend on how these household names have performed in Q2 as per their...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Sell | Neutral | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Strong Sell | Strong Buy |
| Summary | Neutral | Neutral | Neutral | Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 351.02 | 353.71 | 347.70 | -0.93 | -0.26% | 10.85M | NASDAQ | |||
| 2,711.60 | 2,713.20 | 2,668.40 | +14.5 | +0.54% | 840.38K | NASDAQ | |||
| 57.49 | 58.34 | 39.00 | +22.83 | +65.87% | 8.67M | NASDAQ | |||
| 19.73 | 19.83 | 19.00 | +0.47 | +2.44% | 7.00M | NYSE | |||
| 46.31 | 48.59 | 37.17 | +8.63 | +22.90% | 84.87M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 45.45 | 45.52 | 44.07 | +1.50 | +3.40% | 36.74M | NYSE | |||
| 169.12 | 176.31 | 164.80 | -2.67 | -1.55% | 6.45M | NYSE | |||
| 33.84 | 35.15 | 32.78 | -1.36 | -3.86% | 59.06M | NYSE | |||
| 197.75 | 202.20 | 192.22 | +0.25 | +0.13% | 28.06M | NASDAQ | |||
| 54.00 | 54.15 | 53.26 | +0.32 | +0.60% | 12.90M | NASDAQ | |||
| 14.27 | 14.57 | 13.92 | -0.34 | -2.33% | 13.24M | NASDAQ | |||
| 147.76 | 149.55 | 146.58 | -1.10 | -0.74% | 5.02M | NASDAQ | |||
| 197.02 | 197.44 | 192.00 | -3.07 | -1.53% | 19.00M | NYSE | |||
| 13.63 | 13.67 | 13.42 | +0.09 | +0.66% | 2.07M | NYSE |
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
